ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 Phase 3 SPOTLIGHT Study Primary Results: Zolbetuximab + mFOLFOX6 as 1L Treatment for Patients With CLDN18.2+/HER2- Locally Advanced Unresectable/Metastatic Gastric or GEJ Adenocarcinoma
By
ASCO GI 2023 Conference Coverage
FEATURING
Kohei Shitara
By
ASCO GI 2023 Conference Coverage
FEATURING
Kohei Shitara
449 views
January 26, 2023
Login to view comments.
Click here to Login
Videos